Immuneering (IMRX) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Immuneering (IMRX) over the past year, gaining 53.0% versus a loss of 42.5%. Over five years, IMRX leads with a -85.0% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($258.1 million vs $251.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | ZNTL |
|---|---|---|
| Share price | $3.89 | $2.63 |
| Market cap | $251.67M | $258.06M |
| 1-day change | +4.01% | +4.78% |
| YTD return | -43.16% | +85.93% |
| 1-year return | -42.46% | +53.05% |
| 5-year return | -84.96% | -96.65% |
| EPS (TTM) | $-0.93 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $6.95 |
| 52-week low | $3.60 | $1.21 |
| Distance from 52-week high | -54.13% | -62.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +341.39% | +178.71% |
| Average volume | 708.12K | 1.21M |
| Shares outstanding | 64.70M | 98.12M |
| Employees | 57 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed IMRX by 95.5 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
IMRX vs ZNTL FAQ
Which is bigger, Immuneering or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $258.06M compared with $251.67M for Immuneering (IMRX).
Which stock has performed better over the past year, IMRX or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -42.46% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.